From AACR 2021

Abstract

0123456789();: the availability of several new targeted approaches will provide some hope to patients and their clinicians This year’s American Association for Cancer Research (AACR) Annual Meeting was the second virtual iteration, and the first to be entirely planned for this format. Notable features included the availability of a substantial amount of ondemand content and dedicated live discus sion panels for each prerecorded session — both are much appreciated features (although possibly not by discussants based in certain distant time zones). The first clinical plenary session, dedicated to the late Jose Baselga, included encouraging data demonstrating the superior efficacy of the novel immunemobilizing monoclonal TCR against cancer (ImmTAC) tebentafusp over physician’s choice of therapy (including immunecheckpoint inhibitors) for patients with uveal melanoma. This agent was found to substantially prolong overall survival (estimated 1year OS 73.2% versus 57.5%; HR 0.51, 95% CI 0.36–0.71; P < 0.0001) and seems likely to dramatically improve the prognosis of patients with this In the news